Tech Company Financing Transactions
Amplyx Pharmaceuticals Funding Round
Amplyx Pharmaceuticals closed a $40 million financing round on 8/2/2017. Backers included private investors.
Transaction Overview
Company Name
Announced On
8/2/2017
Transaction Type
Venture Equity
Amount
$40,042,102
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 26 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
12730 High Bluff Dr. 160
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Website
Email Address
Overview
Amplyx Pharmaceuticals is developing novel, broad-spectrum antifungal agents for the treatment of life-threatening fungal infections.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Michael Grey
Chief Executive Officer
Ciara Kennedy
Chief Financial Officer
Alan Fuhrman
Chief Medical Officer
Michael Hodges
VP - Bus. Development
Kevin Holme
VP - Operations
Paul Bien
VP - Operations
Pamela Wedel
VP - Regulatory Affairs
Elizabeth Gordon
Browse more venture capital transactions:
Prev: 8/2/2017: FluGen venture capital transaction
Next: 8/2/2017: Minjar venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs